Search Results - "Goss, Geraldine"

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial by Antill, Yoland, Kok, Peey-Sei, Robledo, Kristy, Yip, Sonia, Cummins, Michelle, Smith, Deborah, Spurdle, Amanda, Barnes, Elizabeth, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Andrews, John, Stockler, Martin R, Mileshkin, Linda

“…BackgroundIn this study, we assessed the activity of durvalumab, an antibody to programmed death ligand-1, in two cohorts of women with advanced endometrial…”
Get full text

Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas by HEYMACH, John V, DESAI, Jayesh, SILVERMAN, Stuart G, CONNORS, Susan, FOLKMAN, Judah, FLETCHER, Christopher D. M, DEMETRI, George D, MANOLA, Judith, DAVIS, Darren W, MCCONKEY, David J, HARMON, David, RYAN, David P, GOSS, Geraldine, QUIGLEY, Travis, VAN DEN ABBEELE, Annick D

“…Purpose: SU5416 (semaxanib) is a small molecule inhibitor of the vascular endothelial growth factor (VEGF) receptor-2 and KIT receptor tyrosine kinases. This…”
Get full text

Malignant epithelioid angiomyolipoma ('sarcoma ex angiomyolipoma') of the kidney : A case report and review of the literature by CIBAS, Edmund S, GOSS, Geraldine A, KULKE, Matthew H, DEMETRI, George D, FLETCHER, Christopher D. M

“…Malignant epithelioid angiomyolipoma is a recently described rare tumor of the kidney. Its existence has been questioned, however, on the basis of incomplete…”
Get full text

An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells by GRANT, Susan L, HAMMACHER, Annet, DOUGLAS, Andrea M, GOSS, Geraldine A, MANSFIELD, Rachel K, HEATH, John K, BEGLEY, C. Glenn

“…Oncostatin M (OSM), an interleukin-6 type cytokine, acts via the gp130 signaling receptor to inhibit proliferation and induce differentiation of breast cancer…”
Get full text

Expression and function of members of the cytokine receptor superfamily on breast cancer cells by DOUGLAS, A. M, GOSS, G. A, SUTHERLAND, R. L, HILTON, D. J, BERNDT, M. C, NICOLA, N. A, BEGLEY, C. G

“…Receptors for the cytokines leukemia inhibitory factor (LIF), interleukin-6 (IL-6), oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and interleukin-11…”
Get full text

Abstract PS13-36: Prevention of chemotherapy-induced alopecia: A prospective study in breast and ovarian cancer patients by Papadopoulos, Lia A, Chua, Susan, Goss, Geraldine, Johnson, Jane, Ling, Aaron, Devitt, Bianca

“…Abstract Background: Scalp cooling minimises chemotherapy-induced alopecia (CIA) which may reduce distress, improve quality of life and body image. This study…”
Get full text

Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC) by Ananda, Sumitra, Wang, Yuxuan, Hong, Wei, Richardson, Gary Edward, Lombard, Janine Margaret, Goss, Geraldine, Mileshkin, Linda R., Steer, Christopher B., Lennon, Anne Marie, McNally, Orla, Douville, Christopher B, Popoli, Maria, Ptak, Janine, Silliman, Natalie, Dobbyn, Lisa, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Tie, Jeanne, Gibbs, Peter

“…5553 Background: The management of EOC remains challenging, with a high risk of relapse despite surgery, chemotherapy and maintenance therapy. Detection of…”
Get full text

Quality of life (QoL) in patients with recurrent ovarian clear cell carcinoma (rOCCC) receiving durvalumab (D) versus physician’s choice chemotherapy (PCC) in the randomized phase II MOCCA/APGOT-OV2/GCGS-OV3 trial by Ngoi, Natalie YL, Sun, Haoyang, Choi, Chel Hun, Heong, Valerie, Ow, Samuel Guan Wei, Chay, Wen Yee, Kim, Hee Seung, Goss, Geraldine, Goh, Jeffrey C., Lin, Meiqi, Lim, Diana, Kim, Jae-Weon, Friedlander, Michael, Tai, Bee Choo, Kim, Kidong, Tan, David Shao Peng

“…e17564 Background: In the phase II MOCCA/ APGOT-OV2/ GCGS-OV3 trial, D was not superior to PCC in prolonging progression-free survival in patients with rOCCC…”
Get full text

Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 Trial by Post, Cathalijne C.B., de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Nelleke (P.) B., Ledermann, Jonathan A., Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie Hélène, Kitchener, Henry C., Nijman, Hans W., Lutgens, Ludy C.H.W., Brooks, Susan, Jürgenliemk-Schulz, Ina M., Feeney, Amanda, Goss, Geraldine, Fossati, Roldano, Ghatage, Prafull, Leary, Alexandra, Do, Viet, Lissoni, Andrea A., McCormack, Mary, Nout, Remi A., Verhoeven-Adema, Karen W., Smit, Vincent T.H.B.M., Putter, Hein, Creutzberg, Carien L.

“…The survival results of the PORTEC-3 trial showed a significant improvement in both overall and failure-free survival with chemoradiation therapy versus pelvic…”
Get full text

A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3) by Tan, David Shao Peng, Choi, Chel Hun, Ngoi, Natalie, Sun, Haoyang, Heong, Valerie, Ow, Samuel Guan Wei, Chay, Wen Yee, Kim, Hee Seung, Lim, Yi Wan, Goss, Geraldine, Goh, Jeffrey C., Luo, Vilianty, Tai, Bee Choo, Lim, Diana, Kaliaperumal, Nivashini, AU, Veonice Bijin, Connolly, John, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong

“…5565 Background: The optimal treatment of recurrent ovarian clear cell carcinoma (rOCCC) remains unknown. Prior data suggests rOCCC is a chemo-resistant…”
Get full text

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial by Colombo, Nicoletta, Biagioli, Elena, Harano, Kenichi, Galli, Francesca, Hudson, Emma, Antill, Yoland, Choi, Chel Hun, Rabaglio, Manuela, Marth, Christian, Parma, Gabriella, Fariñas-Madrid, Lorena, Nishio, Shin, Allan, Karen, Lee, Yeh Chen, Piovano, Elisa, Pardo, Beatriz, Nakagawa, Satoshi, McQueen, John, Zamagni, Claudio, Manso, Luis, Takehara, Kazuhiro, Ferrero, Annamaria, Tognon, Germana, Lissoni, Andrea Alberto, Petrella, Mariacristina, Laudani, Maria Elena, Uggeri, Sara, Barretina Ginesta, M Pilar, Casanova, Claudia, Arcangeli, Valentina, Antonuzzo, Lorenzo, Gadducci, Angiolo, Cosio, Stefania, McNeish, Ian, Tookman, Laura, Redondo Sanchez, Andrés, Choi, Chel Hun, Baldini, Editta, Palaia, Innocenza, Benedetti Panici, Pierluigi, Takahashi, Nobutaka, Lombard, Janine, Ardizzoia, Antonio, Bologna, Alessandra, Herrero Ibáñez, Ana Maria, Musolino, Antonino, Márquez Vázquez, Raúl, Pietzner, Klaus, Braicu, Elena, Heinzelmann-Schwarz, Viola A., Powell, Melanie, Yokoyama, Yoshihito, Abeni, Chiara, Cueva, Juan Fernando, Trillsch, Fabian, Ataseven, Beyhan, Petru, Edgar, Heubner, MartinLeonhard, Sadozye, Azmat Hassanq, Dubey, Sidharth, Tiley, Susan, Chrystal, Kathryn, Kim, Sang Wun, Fehr, Mathias, Scatchard, Kate, Anand, Anjana, Taylor, Alexandra, Enomoto, Takayuki, Yoshihara, Kosuke, Selva-Nayagam, Sudarsha, Karki, Bhaskar, Wilkinson, Kate, Chantrill, Lorraine, Lee, Chulmin, Bertolini, Alessandro, Narducci, Filomena, Bellotti, Giovanna, Fusco, Vittorio, Aebi, Stefan, Del Grande, Maria, Tokunaga, Hideki, Shigeta, Shogo, Goss, Geraldine, Siow, Zhen Rong, Steer, Christopher, Lee, Kwang-Beom, Di Meglio, Giovanni, Massa, Elena, De Marino, Elvira, Tortora, Vincenzo, Palacio Vazquez, Isabel, Tsuji, Kosuke, Tominaga, Eiichiro, Black, Allison, So, Kyeong A, Suh, Dong Hoon, Lee, Keun Ho, Fossati, Roldano, Carlucci, Luciano, Barberis, Massimo

“…At the time of AtTEnd trial design, standard treatment for advanced or recurrent endometrial cancer included carboplatin and paclitaxel chemotherapy. This…”
Get full text

Patients’ and clinicians’ preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial by Blinman, Prunella, Mileshkin, Linda, Khaw, Pearly, Goss, Geraldine, Johnson, Carol, Capp, Anne, Brooks, Susan, Wain, Gerard, Kolodziej, Ilka, Veillard, Anne-Sophie, O'Connell, Rachel, Creutzberg, Carien L, Stockler, Martin R

“…Background: To determine the minimum survival benefits that patients, and their clinicians, judged sufficient to make adjuvant chemotherapy (ACT) worthwhile,…”
Get full text

Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601) by Smith, Deborah, Robledo, Kristy, Yip, Sonia, Cummins, Michelle, Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally E., Shannon, Catherine M., Coward, Jermaine, Beale, Philip James, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine Margaret, Spurdle, Amanda B., Andrews, John, Stockler, Martin R., Mileshkin, Linda R., Antill, Yoland Catherine

“…Abstract only 5584 Background: Activity of durvalumab in patients with deficient mismatch repair (dMMR) advanced endometrial carcinoma (EC) was confirmed in…”
Get full text

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA) by Ngoi, Natalie Yl, Heong, Valerie, Ow, Samuel, Chay, Wen Yee, Kim, Hee Seung, Choi, Chel Hun, Goss, Geraldine, Goh, Jeffrey C, Tai, Bee Choo, Lim, Diana Gz, Kaliaperumal, Nivashini, Au, Veonice B, Connolly, John E, Kim, Jae-Weon, Friedlander, Michael, Kim, Kidong, Tan, David Sp

“…The optimal treatment of recurrent ovarian clear cell carcinoma remains unknown. There is increasing rationale to support the role of immune checkpoint…”
Get more information

Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601) by Antill, Yoland Catherine, Kok, Peey Sei, Robledo, Kristy, Barnes, Elizabeth, Friedlander, Michael, Baron-Hay, Sally E., Shannon, Catherine M., Coward, Jermaine, Beale, Philip James, Goss, Geraldine, Meniawy, Tarek, Yip, Sonia, Smith, Deborah, Spurdle, Amanda B., Parry, Michelle, Andrews, John, Kelly, Marzena, Stockler, Martin R., Mileshkin, Linda R.

“…Abstract only 5501 Background: Deficient DNA mismatch repair (dMMR) occurs in approximately 15% of AEC and is associated with a high tumour mutation burden…”
Get full text

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA) by Smith, Deborah, Robledo, Kristy P, Yip, Sonia, Cummins, Michelle M, Kok, Peey-Sei, Lee, Yeh Chen, Friedlander, Michael, Baron-Hay, Sally, Shannon, Catherine, Coward, Jermaine, Beale, Philip, Goss, Geraldine, Meniawy, Tarek, Lombard, Janine, Spurdle, Amanda B, Andrews, John, Stockler, Martin R, Mileshkin, Linda, Antill, Yoland

“…Women with advanced endometrial carcinoma (EC) with mismatch repair (MMR) deficiency have improved outcomes when treated with immune checkpoint inhibitors;…”
Get full text

Medical management of unresectable, recurrent low-grade retroperitoneal liposarcoma: integration of cytotoxic and non-cytotoxic therapies into multimodality care by Goss, Geraldine, Demetri, George

“…Liposarcomas of the retroperitoneum are rare tumors, and best managed by an expert multidisciplinary team consisting of a surgical oncologist with appropriate…”
Get full text

Oncostatin M induces the differentiation of breast cancer cells by Douglas, Andrea M., Grant, Susan L., Gross, Geraldine A., Clouston, David R., Sutherland, Robert L., Begley, C. Glenn

“…We have recently described the action of Oncostatin M (OSM) to inhibit the proliferation of breast cancer cells. In this study we examined the action of OSM on…”
Get full text

Oncostatin M and Leukemia Inhibitory Factor Regulate the Growth of Normal Human Breast Epithelial Cells by Grant, Susan L., Douglas, Andrea M., Goss, Geraldine A., Begley, C. Glenn

“…We have previously reported the inhibitory effects of oncostatin M (OSM) and leukemia inhibitory factor (LIF) on the proliferation of breast cancer cell lines…”
Get full text

Pentastarch as partial replacement fluid for therapeutic plasma exchange: Effect on plasma proteins, adverse events during treatment, and serum ionized calcium by Goss, Geraldine A., Weinstein, Robert

“…We compared the safety, effect on plasma proteins, and contribution to hypocalcemic toxicity of 10% pentastarch vs. 5% albumin in plasma exchange. Thirty‐two…”
Get full text